AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02583685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR4 + LDV/SOF + SMV 8 wk
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study NCT02583685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR4 + LDV/SOF + ASV 12 wk
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Study NCT02583685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR4 + LDV/SOF + SMV 12 wk
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study NCT00308763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.~If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off.
Study NCT00308763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Release Bupropion
Description: Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
Study NCT02701673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
Study NCT02701673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Study NCT02701673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
Study NCT02701673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
Study NCT02701673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
Study NCT02701673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
Study NCT02701673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
Study NCT02701673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 60 mg/m2 by vein on Days -3 and -2.
Study NCT02701673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell transplant performed on Day 0.
Study NCT00808743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib: 400mg twice daily, orally, 6 months
Study NCT00808743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib: 400mg twice daily, orally, 6 months
Study NCT00808743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses
Study NCT00808743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses
Study NCT03927482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARES mobile smart phone app
Description: The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
Study NCT03927482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Check Your Drinking
Description: Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
Study NCT03959423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHCL insulin pump system
Description: 670G 4.0 system with GS3; 780G system with G4S (continued access phase);
Study NCT02133300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Study NCT01362010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Minocycline Foam FXFM244
Description: Topically applied once a day.
Study NCT03669315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic stimulation
Description: Neuromodulation tool
Study NCT03669315 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic stimulation
Description: Neuromodulation tool
Study NCT01790503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Study NCT01790503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT01790503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT00510809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Policosanol
Description: Policosanol 20 mg daily
Study NCT00510809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study NCT00510809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Policosanol Plus Already In Use Statin Therapy
Description: Policosanol 20 mg daily Statin Therapy
Study NCT00070941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-e
Description: oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.
Study NCT01787058 — intervention group
Intervention type: OTHER
Intervention: Dubai Cares beneficiary
Description: Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
Study NCT01798836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol
Study NCT01798836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist or antagonist protocol without oestradiol pre-treatment
Study NCT01474668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single oral dose\\n \\n\\n\\n\\n
Study NCT02865564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Study NCT02865564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02865564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin and gentamicin
Study NCT02865564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ampicillin and gentamicin
Study NCT03947242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib and Trastuzumab plus Vinorelbine
Description: Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
Study NCT03806803 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized fecal microbiota transplant
Description: 15 capsules
Study NCT03806803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized sterile fecal filtrate
Description: 15 capsules
Study NCT02543671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 enriched, reduced-fat yellow cheese
Description: 60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
Study NCT02543671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: plain (non-fortified) reduced-fat yellow cheese
Description: 60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
Study NCT01938547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Study NCT02215083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: 10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
Study NCT05844722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention therapy
Description: Mindfulness-based cognitive therapy consists of meditation techniques to stay in the present moment with acceptance (breathing exercises, body scan, gentle yoga, awareness of thoughts and feelings) and some aspects of cognitive therapy, and psycho-education.
Study NCT05844722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care means received standard multidisciplinary stroke care
Study NCT01362010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: Topically applied once a day.
Study NCT03571698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulator
Description: The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
Study NCT01702636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study NCT01702636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03053206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADE Protocol
Description: ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days
Study NCT02380768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain (size 1.5 or size 2.0)
Description: The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
Study NCT02380768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme (size 1.5 or size 2.0)
Description: The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
Study NCT03389048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMD-200
Description: The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
Study NCT03389048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SLR
Description: With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
Study NCT00070941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral escitalopram
Description: 20mg or 30mg daily in two divided doses, along with placebo SAM-e.
Study NCT00070941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
Study NCT03881969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Payment of £100
Description: No financial payment
Study NCT00470080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venepuncture
Description: venepuncture
Study NCT03038646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-101
Study NCT04299100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health Program for Participants with No/Mild Sleep Apnea
Description: Participants randomized to the Sleep Health Program will receive the Self-Management for Sleep Care videos and digital materials.
Study NCT04299100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health Program for Participants with Moderate/Severe Sleep Apnea
Description: Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea will receive the Self-Management for Sleep Care videos and digital materials, and be recommended for referral to a sleep clinic as part of standard of care.
Study NCT04926935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological analysis of blood samples.
Description: Microbiological analysis of blood samples collected from the patients with clinically suspected infection.
Study NCT00559273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: 1.2 mcg/kg SC monthly, starting dose
Study NCT00559273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: 0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
Study NCT02603744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraovarian injection of Adipose derived Stromal cells (ADSCs)
Description: Intra-ovarian injection of Adipose derived mesenchymal stem cells.
Study NCT03387787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoTab
Description: The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data.~Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days.
Study NCT03387787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: During the study, patients will be treated with basal Insulin degludec
Study NCT02917460 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic sequencing and molecular diagnostic results, if any
Description: Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
Study NCT04619394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic exercise - own monitors program
Description: Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes.
Study NCT04619394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic exercise - AIPAP program
Description: Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes.
Study NCT00536172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
Study NCT00536172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo distribution matches the active medication.
Study NCT02276859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
Study NCT02276859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin lispro
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Study NCT02276859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
Study NCT01858233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Modification
Description: Intensive dietary counseling, increased physical activity, lactation counseling
Study NCT01424735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycobacterium w.(Mw)-freeze dried extract 0.5ml
Description: 0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
Study NCT03966326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane and fentanil
Description: Patients will receive standard general anesthesia
Study NCT03966326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane and fentanil plus PECS II block
Description: Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
Study NCT02455401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose remifentanil
Description: Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
Study NCT02455401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose remifentanil
Description: Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
Study NCT02455401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No remifentanil
Description: Intervention: no remifentanil will be administrated
Study NCT00505947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: infliximab 5 mg/Kg body weight by intravenous infusion